The Clinical Data Interchange Standards Consortium
(CDISC) is delighted to announce the opening of a branch of the CDISC European Foundation in Hong Kong. Hong Kong was chosen for its centralized location in the fastest growing market in the world, and represents a significant opportunity for CDISC to expand the global adoption of CDISC standards. “Our presence in Hong Kong reflects our commitment to our existing and new members in the Asia-Pacific region. This includes existing member companies in such Asia-Pacific countries as Japan, China, South Korea, India, Thailand, Singapore and Australia. We at CDISC want to ensure that our members in this region feel that they have an outlet and are represented,” stated Sheila Leaman, CDISC Director of Global Relations.
After a vision that took nine months to come to fruition, the registration of the Hong Kong branch was finalized on 7 May 2013. “We are extremely pleased to announce our new CDISC Hong Kong branch,” said Dr. Rebecca Kush, CDISC President and CEO. “After discussions within CDISC Operations last year, we determined to proceed through our CDISC European Foundation entity to allow for a swifter process, and are glad that we will now have representation for our members in the Asia-Pacific region.”
Incidentally, after CDISC’s successful Interchange in Singapore in February 2013, attendees were interested in continuing to have a CDISC conference in the region. As such, CDISC is planning to have the next CDISC Asia-Pacific Interchange in Hong Kong in the summer of 2014 as a way to continue to provide value to our members and spread the message about CDISC standards in the region.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.